TG Therapeutics, Inc. (0VGI.L)
USD 32.28
(-6.35%)
USD 32.28
(-6.35%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 100.11 Million USD | 22.88% |
| 2022 | 81.47 Million USD | 6.32% |
| 2021 | 76.63 Million USD | 322.74% |
| 2020 | 18.12 Million USD | -53.74% |
| 2019 | 39.18 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 64.52 Thousand USD | -97.4% |
| 2012 | 2.47 Million USD | -38.13% |
| 2011 | 4 Million USD | -76.09% |
| 2010 | 16.75 Million USD | 2403.97% |
| 2009 | 669.22 Thousand USD | -43.73% |
| 2008 | 1.18 Million USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 102.53 Million USD | 1.2% |
| 2024 Q1 | 101.32 Million USD | 1.21% |
| 2023 Q3 | 9.52 Million USD | -2.89% |
| 2023 Q2 | 9.8 Million USD | -2.72% |
| 2023 FY | 100.11 Million USD | 22.88% |
| 2023 Q4 | 100.11 Million USD | 951.44% |
| 2023 Q1 | 10.07 Million USD | -87.63% |
| 2022 FY | 81.47 Million USD | 6.32% |
| 2022 Q4 | 81.47 Million USD | 1.07% |
| 2022 Q1 | 77.56 Million USD | 1.22% |
| 2022 Q2 | 78.92 Million USD | 1.75% |
| 2022 Q3 | 80.62 Million USD | 2.15% |
| 2021 Q2 | 10.18 Million USD | -1.58% |
| 2021 Q3 | 10.02 Million USD | -1.63% |
| 2021 Q4 | 76.63 Million USD | 664.82% |
| 2021 FY | 76.63 Million USD | 322.74% |
| 2021 Q1 | 10.34 Million USD | -42.91% |
| 2020 Q3 | 24.88 Million USD | -22.66% |
| 2020 Q4 | 18.12 Million USD | -27.14% |
| 2020 FY | 18.12 Million USD | -53.74% |
| 2020 Q2 | 32.17 Million USD | -18.26% |
| 2020 Q1 | 39.36 Million USD | 0.44% |
| 2019 Q1 | 36.46 Million USD | 0.0% |
| 2019 Q4 | 39.18 Million USD | 2.8% |
| 2019 Q3 | 38.12 Million USD | 4.23% |
| 2019 Q2 | 36.57 Million USD | 0.29% |
| 2019 FY | 39.18 Million USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | -100.0% |
| 2014 Q1 | 115.55 Thousand USD | 79.07% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 Q3 | 2.26 Million USD | -4.05% |
| 2013 FY | 64.52 Thousand USD | -97.4% |
| 2013 Q4 | 64.52 Thousand USD | -97.16% |
| 2013 Q2 | 2.36 Million USD | -2.45% |
| 2013 Q1 | 2.42 Million USD | -2.21% |
| 2012 FY | 2.47 Million USD | -38.13% |
| 2012 Q1 | 4.66 Million USD | 16.42% |
| 2012 Q3 | 4.38 Million USD | -0.33% |
| 2012 Q2 | 4.39 Million USD | -5.78% |
| 2012 Q4 | 2.47 Million USD | -43.4% |
| 2011 Q3 | 16.84 Million USD | 0.69% |
| 2011 Q4 | 4 Million USD | -76.21% |
| 2011 Q1 | 16.6 Million USD | -0.91% |
| 2011 Q2 | 16.72 Million USD | 0.74% |
| 2011 FY | 4 Million USD | -76.09% |
| 2010 Q1 | 16.44 Million USD | 2357.64% |
| 2010 FY | 16.75 Million USD | 2403.97% |
| 2010 Q4 | 16.75 Million USD | 0.87% |
| 2010 Q3 | 16.61 Million USD | 0.7% |
| 2010 Q2 | 16.49 Million USD | 0.31% |
| 2009 Q3 | 1.77 Million USD | 4.66% |
| 2009 Q1 | 1.62 Million USD | 36.42% |
| 2009 Q4 | 669.22 Thousand USD | -62.39% |
| 2009 Q2 | 1.7 Million USD | 4.78% |
| 2009 FY | 669.22 Thousand USD | -43.73% |
| 2008 Q3 | - USD | 0.0% |
| 2008 FY | 1.18 Million USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | 1.18 Million USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | -100.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | 324.39 Thousand USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | -310.791% |
| Dynavax Technologies Corporation | 252.41 Million USD | 60.336% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -201.597% |
| Perrigo Company plc | 3.63 Billion USD | 97.244% |
| Illumina, Inc. | 1.48 Billion USD | 93.276% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.68% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -9911.8% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 98.755% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.227% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 42.379% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 96.296% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -325.328% |
| Waters Corporation | 2.3 Billion USD | 95.657% |
| Biogen Inc. | 7.18 Billion USD | 98.607% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -198.726% |
| Evolus, Inc. | 120.35 Million USD | 16.817% |
| Adicet Bio, Inc. | 17.7 Million USD | -465.543% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -170.013% |
| bluebird bio, Inc. | 224.41 Million USD | 55.388% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 80.038% |
| FibroGen, Inc. | 89.69 Million USD | -11.618% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 96.339% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -2991.368% |
| Homology Medicines, Inc. | 43.17 Million USD | -131.883% |
| Geron Corporation | 35.05 Million USD | -185.635% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 95.727% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 74.187% |
| Myriad Genetics, Inc. | 130.9 Million USD | 23.516% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -10596.368% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -3.484% |
| Zoetis Inc. | 6.56 Billion USD | 98.475% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -2174.375% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 94.932% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 83.119% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 86.185% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -192.828% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 92.851% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -119.11% |
| Verastem, Inc. | 40.08 Million USD | -149.758% |
| Nektar Therapeutics | 112.62 Million USD | 11.105% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 43.776% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -3156.929% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 91.16% |
| OPKO Health, Inc. | 222.03 Million USD | 54.909% |
| Exelixis, Inc. | 189.94 Million USD | 47.291% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 61.24% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | 23.025% |
| Imunon, Inc. | 1.13 Million USD | -8687.731% |
| Blueprint Medicines Corporation | 610.96 Million USD | 83.613% |
| Insmed Incorporated | 1.19 Billion USD | 91.61% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 93.322% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -75.683% |
| Incyte Corporation | 29.16 Million USD | -243.317% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 77.577% |